IP Library Patent Application 14290438
Patent Application
App. No. 14/290,438

Method For Production Of Large Numbers Of Cartilage Cells With Phenotype Retention

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/290,438
Abstract

A method for production of large numbers of cartilage cells with phenotype retention intended for treatment of articular cartilage lesions or preparing viable cartilage tissue by propagation of chondrocytes from cartilage explants, human or animal, with the retention of phenotypes of the cartilage cells, in which cells are chondrocytes retaining morphologic attributes of the same or chondrocyte progenitor cells. The method includes culturing the cells in which cultured cells are organized into mature hyaline cartilage on the surface of biologic structures such as cancellous or cortical bone lamina. The method for culturing chondrocytes to produce three dimensional cellular structures consisting of cartilage cells and cell produced extracellular cartilage matrix.

Claims (20)

1 . A method for production of large numbers of cartilage cells comprises the step of:

preparing viable cartilage tissue by propagation of chondrocytes from cartilage explants, human or animal, with the retention of phenotypes of the cartilage cells.

2 . The method according to claim 1 in which cells are chondrocytes retaining morphologic attributes of the same or chondrocyte progenitor cells.

3 . The method according to claim 1 in which cultured cells are organized into mature hyaline cartilage on the surface of biologic structures such as cancellous or cortical bone lamina.

4 . The method according to claim 1 for culturing chondrocytes to produce three dimensional cellular structure consisting of cartilage cells and cell produced extracellular cartilage matrix.

5 . The method according to claim 1 whereby biologic material comprising hyaline cartilage tissue is propagated on the surface of thin cancellous bone which is undecalcified, and wherein the said cancellous bone lamina is from 0.5 to 2.0 mm in thickness.

6 . The method according to claim 1 whereby cancellous bone lamina, 0.5 to 2.0 mm thick is decalcified to render it flexible.

7 . The method according to claim 1 whereby cancellous bone lamina is either demineralized or undemineralized and is thicker than 2.0 mm.

8 . The method according to claim 5 whereby newly proliferating cartilage can be transplanted into a chondral defect together with the underlying substrate without expanding the cells.

9 . The method according to claim 6 whereby newly proliferating cartilage can be transplanted into a chondral defect together with the underlying substrate without expanding the cells.

10 . The method according to claim 7 whereby newly proliferating cartilage can be transplanted into a chondral defect together with the underlying substrate without expanding the cells.

11 . The method according to claim 1 whereby a substrate on which chondrocytes proliferate from explants is a lamina of undecalcified cortical bone 0.5 to 2.0 mm thick with multiple, geometrically placed perforations.

12 . The method according to claim 1 whereby the lamina on which explants are placed is decalcified cortical bone plate 0.5 to 2.0 mm thick with multiple, geometrically placed perforations.

13 . The method according to claim 1 whereby all osseous substrates on which chondrocytes have proliferated from cartilage explants are cryopreserved for further transplantation.

14 . The method according to claim 1 whereby cartilage explants are cultivated on a cellular dermis, pericardium, dura mater and fascia with or without perforations.

15 . The method according to claim 1 whereby chondrocytes proliferated on soft membranes with or without perforations are cryopreserved for future transplantation.

16 . The method according to claim 1 whereby cartilage explants are placed on Gelfoam®, Surgicel®, Gelatin USP, and or similar materials which can be optionally supplemented with thrombin or ligrin.

17 . The method according to claim 1 whereby cartilage explants are grown on membranes of collodion, polyvinylpyrrolidone, hydroxyethyl starch or an equivalent thereof.

18 . The method according to claim 1 whereby cartilage cells together with or without cartilage explants are harvested mechanically, enzymatically or physically from the substrates on which they are grown, frozen and either freeze-dried or dehydrated under hypothermia and micronized for implantation into articular defects.

19 . The method according to claim 18 wherein cells and explants can be frozen with substrates and then later scraped with a blade for further processing.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Aug 29, 2022
From: BANKUNITED, N.A.
To: VIVEX BIOLOGICS GROUP, INC.
Reel/Frame 061333/0853 →
RELEASE OF SECURITY INTEREST Recorded Dec 12, 2019
From: HERITAGE BANK OF COMMERCE
To: VIVEX BIOMEDICAL, INC.; UMTB BIOMEDICAL, INC; ADVANCED NUMED TECHNOLOGIES, LTD.; VIVEX BIOMEDICAL INTERNATIONAL, INC.
Reel/Frame 051282/0653 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Dec 11, 2019
From: VIVEX BIOLOGICS GROUP, INC.
To: BANKUNITED, N.A.
Reel/Frame 051260/0064 →
CHANGE OF NAME Recorded Aug 16, 2019
From: VIVEX BIOMEDICAL, INC.
To: VIVEX BIOLOGICS, INC.
Reel/Frame 050079/0179 →
CHANGE OF NAME Recorded Aug 16, 2019
From: VIVEX BIOLOGICS, INC.
To: VIVEX BIOLOGICS GROUP, INC.
Reel/Frame 050079/0225 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 7, 2014
From: MALININ, THEODORE I
To: VIVEX BIOMEDICAL, INC.
Reel/Frame 033250/0301 →